Jessica Ailani, AAN 2021: Phase 3 ADVANCE Study Results

We had the great pleasure to meet with Jessica Ailani (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the Phase 3 ADVANCE study results investigating atogepant for the treatment of migraine. The abstract entitled: ‘Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine‘ was […]

Jerry Mendell, AAN 2021: The Investigation of SRP-9001 Gene Transfer Therapy in DMD

It was a pleasure to meet with Jerry Mendell (Nationwide Children’s Hospital, Columbus, OH, USA) to discuss his recent work in the gene-delivery clinical trial of rAAVrh74.MHCK7.micro-dystrophin (SRP-9001) for Duchenne Muscular Dystrophy. The abstract entitled: ‘A Multicenter Randomized, Double-Blind, Placebo-Controlled, Gene-Delivery Clinical Trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne Muscular Dystrophy’ was presented at the American Academy […]

Sabrina Paganoni, AAN 2021: CENTAUR Trial of AMX0035 for ALS

It was a pleasure to meet with Sabrina Paganoni (Harvard Medical School, Boston, MA, USA) to discuss the CENTAUR study findings, and where AMX0035 is likely to be placed in the treatment paradigm for amyotrophic lateral sclerosis (ALS). The abstract entitled: ‘Long-Term Survival of Participants in the CENTAUR Trial of AMX0035 for ALS’ was presented […]

Anthony Traboulsee, AAN 2021: The use of Tolebrutinib in Relapsing Multiple Sclerosis Treatment

TouchNEUROLOGY had the pleasure of meeting with Anthony (Tony) Traboulsee (University of British Columbia, Vancouver, Canada) to discuss the Phase 2b study investigating tolebrutinib in patients with highly active relapsing multiple sclerosis. The abstract entitled: ‘Efficacy and Safety of Tolebrutinib in Patients With Highly Active Relapsing MS: Subgroup Analysis of the Phase 2b Study’ was […]

Neuropathy Associated with Hereditary Transthyretin Amyloidosis—Diagnosis and Management

US Neurology. 2020;16(2):103–9 DOI: https://doi.org/10.17925/USN.2020.16.2.103

Hereditary transthyretin amyloidosis (hATTR) is a progressive life-threatening disease that typically presents as progressive sensorimotor polyneuropathy, restrictive cardiomyopathy, or a combination of both.1 Patients with hATTR-associated polyneuropathy (hATTR-PN) typically require assistance walking after 5–6 years, and die within 7–10 years from the onset of neuropathy.2 However, clinical manifestations of amyloidosis can affect other organs as well, including […]

Cenobamate for the Treatment of Focal Seizures

US Neurology. 2020;16(2):87–97 DOI: https://doi.org/10.17925/USN.2020.16.2.87

Epilepsy is a very common neurological disease, affecting more than 50 million people worldwide and 3.4 million people in the USA.1–3 Focal seizures, formerly partial-onset seizures, are the most common type, making up ≥60% of cases.4–6 Patients with epilepsy have an increased risk of morbidity and mortality, a decreased quality of life and are more likely […]

Olfaction in Parkinson’s Disease – A Clinical Approach

European Neurological Review. 2020;15(1):37–40 DOI: https://doi.org/10.17925/ENR.2020.15.1.37

Olfactory loss has been extensively studied in Parkinson’s disease (PD) and is now widely acknowledged as one of the major non-motor symptoms of the disease, which precedes the occurrence of clinical motor symptoms.1,2 It is found in around 90% of patients with PD,3–5 and has been considered as a supportive criterion in clinical PD diagnosis according to […]

Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis

US Neurology. 2020;16(2):99–102 DOI: https://doi.org/10.17925/USN.2020.16.2.99

Multiple sclerosis (MS) is a chronic neuro-inflammatory condition estimated to affect over two million people worldwide. Several subtypes of MS have been described, and they are defined by their clinical phenotypes.1 The majority of patients initially exhibit relapsing remitting MS (RRMS), which is characterized by acute episodes of overt inflammation associated with abrupt clinical decline, most […]